Full-Time
Consumer Sciences and Product Intelligence Director
Wellness
Haleon
10,001+ employees
Global consumer health care products company
Compensation Overview
$202.7k - $278.8k/yr
Warren, NJ, USA + 1 more
More locations: Richmond, VA, USA
Hybrid
Three days on-site per week required.
Bachelor's, Master's
 Biology & Biotech (1) |
|---|
Get referred to Haleon
See people who can refer or advise you
- A bachelor's degree in Market Research, Consumer Science, Business, Psychology, Social Sciences, Marketing, Life Sciences, or a related field.
- At least 10 years of relevant experience within Consumer Packaged Goods, Consumer Health, Food and Beverage, Consumer Insights, Market Research, Product Intelligence, or related industries.
- Experience translating consumer insights into product innovation, business decisions, and measurable commercial outcomes.
- Demonstrated experience leading consumer research, product intelligence, insights, sensory science, or related functions.
- Experience operating in highly matrixed organizations and influencing cross-functional stakeholders.
- Strong business acumen with the ability to engage and influence technical and commercial audiences.
- Experience leading teams and managing geographically dispersed organizations.
- Excellent communication, collaboration, and stakeholder management skills.
- Demonstrated ability to manage multiple priorities while driving strategic outcomes.
- Lead the Consumer First strategy for the Wellness category, ensuring consumer needs, insights, and experiences are integrated throughout the innovation lifecycle.
- Deliver consumer science activities across the stage-gate innovation process, including consumer ethnography, product evaluation, prototype validation, claims support, and post-launch assessment.
- Drive product intelligence capabilities by monitoring market dynamics, consumer behaviors, competitive products, and emerging trends to inform innovation and portfolio strategy.
- Translate consumer insights into actionable recommendations that influence product development, portfolio optimization, and commercial decision-making.
- Establish and maintain testing methodologies, consumer research processes, and product validation frameworks to support innovation excellence.
- Integrate consumer research, product intelligence, consumer complaints, competitive intelligence, and market signals into a unified view of category opportunities and risks.
- Lead prioritization of Consumer Sciences and Product Intelligence resources across the Wellness portfolio.
- Manage a globally distributed team, fostering engagement, talent development, performance, and career growth.
- Partner with Research and Development, Commercial, Marketing, Supply Chain, Operational Units, and external partners to ensure consumer insights drive business outcomes.
- Provide leadership and mentorship across the Wellness and Global Consumer Sciences and Product Intelligence organizations while helping establish future capability within the Wellness category.
- A master's degree or advanced degree in a relevant discipline.
- Experience within Vitamins, Minerals and Supplements, Wellness, Consumer Health, or related categories.
- Experience building consumer science, insights, or product intelligence capabilities within large organizations.
- Demonstrated success leading global teams and driving organizational change.
- Strong understanding of consumer research methodologies, ethnography, product testing, and insight generation.
- Ability to balance strategic leadership with operational execution in a fast-paced environment.
- Demonstrated ability to influence business strategy through data-driven consumer understanding.
Haleon is a global consumer health company that develops and sells everyday health products under brands such as Sensodyne, Advil, and Centrum. Its products address oral care, pain relief, immunity, and general well-being, working through science-backed formulations people use daily. Haleon differentiates itself by being a focused, standalone consumer health business formed from GSK’s spin-off and built from leading brands through major acquisitions, operating at scale with a portfolio of category leaders and competing with peers like Kenvue and Procter & Gamble. Its goal is to help people take control of their daily health with trusted products, while expanding its global reach and investing in manufacturing capacity and brand development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Weybridge, United Kingdom
Founded
2022
Get referred to Haleon
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 organic growth reached 2.6%; Q2 improved to 3.1% with North America rebound.
- Emerging markets grew 6.3% in Q2 2026, led by China, India, and Latin America.
- Haleon priced a $2 billion bond on August 13, 2026, refinancing March 2027 notes.
What critics are saying
- Haleon terminated Eroxon U.S. rights on June 29, 2026 after slower-than-expected sales.
- July 30, 2026 litigation revived claims over Advil Sinus maximum-strength labeling.
- June 4, 2026 Gas-X recall and sub-4% growth against a 4%-6% target threaten valuation.
What makes Haleon unique
- Haleon owns category-leading brands like Sensodyne, Advil, Panadol, and Centrum across 170 markets.
- Its June 29, 2026 Microsoft partnership embeds AI across operations, data, and productivity.
- Oral health innovation keeps driving share gains; H1 2026 oral health grew 7.3%.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Paid Parental Leave
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%Haleon's US subsidiary, Haleon US Capital LLC, has launched and priced a $2 billion fixed-rate bond offering. The offering comprises three tranches: $600 million in notes maturing in 2029 with a 4.625% coupon, $600 million in notes maturing in 2031 with a 4.875% coupon, and $800 million in notes maturing in 2036 with a 5.375% coupon. The offering is scheduled to settle on 21 August 2026. Payment of principal and interest is fully guaranteed by Haleon plc. The company plans to use the net proceeds, together with cash on hand if necessary, to repurchase its outstanding $1,999,350,000 3.375% fixed rate senior notes due March 2027 and for general corporate purposes. Barclays Capital, BofA Securities, Deutsche Bank Securities, Goldman Sachs and Mizuho Securities acted as joint book-running managers.
Daniela Cavinatto appointed general manager of Canada division for Haleon Canada. Daniela Cavinatto joins the consumer health company with more than 25 years of international leadership experience. Haleon Canada has appointed Daniela Cavinatto as its new general manager of the Canada division. Cavinatto joins the consumer health company with more than 25 years of international leadership experience. In her new position, she will lead Haleon's Canadian operations as the company works to strengthen its market leadership and expand its portfolio of consumer health brands, including Advil, Sensodyne, and Centrum. Industry experience across global markets. Prior to joining Haleon, Cavinatto served as general manager, Canada for The LEGO Group. During her time there, she led business growth by redefining market strategy, strengthening customer partnerships, and optimizing commercial investments. Throughout her career, Cavinatto has held senior executive roles across North America, Latin America, and Europe. Her background spans general management, sales, marketing, customer development, eCommerce, retail operations, and supply chain. "Daniela is an accomplished business leader with a proven ability to unlock growth, navigate complexity and deliver results in dynamic markets," said Nathalie Gerschtein, the Haleon North America president. "Canada is an important growth market for Haleon, and Daniela brings the commercial acumen, global perspective and leadership experience needed to help us build on our momentum. I am delighted to welcome Daniela to our North American leadership team and look forward to working with her as we strengthen our trusted brand portfolio and advance our leadership in consumer health." Portfolio reach and growth strategy. Haleon's Canadian product lineup holds a strong presence across retail channels. According to the company, six in 10 Canadian households rely on at least one Haleon brand. As of last year, the 2025 Product of The Year lineup included Tums Chewy Bites with Gas Relief. Cavinatto noted that the reach of the company's product line made the role an exciting opportunity. "Throughout my career, I've been inspired by opportunities to transform businesses, accelerate growth and help teams achieve ambitious goals," Cavinatto said. "That's what makes this opportunity so compelling. Haleon's portfolio of brands is rooted in science and consumer understanding with six in 10 Canadian households relying on at least one of our iconic brands. To lead a business with this kind of reach and impact is a true privilege and an opportunity that deeply inspires me." She added that she looks forward to working with internal teams, retail customers, and commercial partners to support the company's continued growth and innovation across Canada.
Haleon reported H1 2026 results ending 30 July, showing improved organic sales growth of 3.1% in Q2, with volume and mix up 1.4%. North America delivered strong progress at 3.1% growth, driven by shelf resets, innovation, and e-commerce momentum. Operating margin improved 120 basis points at constant currency, supported by supply chain efficiency and gross margin expansion of 140 basis points. Emerging markets achieved 6.3% growth in Q2, with India and Latin America leading performance. EPS grew 12% in H1. However, respiratory health remained weak, reducing organic growth by 150 basis points. Europe proved challenging with only 0.4% growth, whilst Middle East markets including Dubai and Pakistan experienced significant declines. The company acknowledged performing below its 4–6% medium-term growth target, with particular gaps in Europe and the Middle East.
Oral health drives first-half growth at Haleon. 368.40p. 11:52 30/07/26. Haleon reported first-half revenue of £5.60bn on Thursday, up 2.2% on a reported basis and 2.6% organically, with second-quarter organic growth improving to 3.1% as North America strengthened. 10,913.70. 5,926.86. 5,860.81. 24,761.16. 11:51 30/07/26. Adjusted operating profit rose 8.2% at constant currencies to £1.36bn and the adjusted operating margin increased to 24.3%, while adjusted diluted earnings per share rose 12% to 10.3p. Oral Health was the strongest category, with second-quarter growth of 6.2%, while emerging markets grew 6.3%. The consumer healthcare group reiterated its full-year guidance for organic revenue growth of 3% to 5% and high-single-digit adjusted operating profit growth at constant currencies. "We delivered a good first half performance in what remains a challenging consumer environment, with sequential improvement in Q2 and a more balanced price and volume/mix," said chief executive Brian McNamara. Haleon also raised its interim dividend 9% to 2.4p and said it had completed £457m of its planned £500m share buyback for 2026. At 0947 BST, shares in Haleon were down 2.03% at 372p. Reporting by Josh White for Sharecast.com.
Maker of Panadol launches new dual-action Pain Relief Tablets. 29th July 2026 Haleon, the maker of Panadol, is expanding into the dual-action pain relief market with the launch of Panacombo Dual Action Pain Relief 200mg/500mg Film-coated Tablets (ibuprofen & paracetamol). The formulation of two pain-relieving ingredients is designed to be stronger and faster than ibuprofen alone, delivering effective pain relief from multiple pain types, including migraine, headache, backache, dental pain, period pain, joint or muscular pain, and aches linked with cold and flu. Haleon noted that Ibuprofen acid alone only provides effective pain relief in 37-45% of cases, while combining ibuprofen with paracetamol increases effectiveness to 67-70%, highlighting the enhanced pain relief achievable through a combined approach. Expanding the trusted Panadol range, Panacombo Dual Action Tablets are formulated to give your shoppers dual relief in one tablet. Paracetamol helps to block pain signals, and ibuprofen helps stop pain at the source. Monica Michalopoulou, Marketing Director at Haleon, said: "For 70 years, Panadol have been experts in pain relief, trusted to assist consumers with pain when needed. The launch of Panacombo, our dual-action pain-relief solution, expands our range of trusted products, and will offer retailers a strong proposition to help boost sales, encouraging shoppers to trade up and benefit from our trusted brand credentials." Panacombo Dual Action Tablets are rolling out in grocery stores at an RRP of £3.50. The launch will be supported by a wide-reaching consumer media activation and campaign later in the year.